Ticagrelor or Prasugrel for Platelet Inhibition in Acute Coronary Syndrome Patients: The ISAR-REACT 5 Trial

Katharina Mayer; Dario Bongiovanni; Vincent Karschin; Dirk Sibbing; Dominick J. Angiolillo; Heribert Schunkert; Karl Ludwig Laugwitz; Stefanie Schüpke; Adnan Kastrati; Isabell Bernlochner

doi:10.1016/j.jacc.2020.09.586

Ticagrelor or Prasugrel for Platelet Inhibition in Acute Coronary Syndrome Patients: The ISAR-REACT 5 Trial

Katharina Mayer, Dario Bongiovanni, Vincent Karschin, Dirk Sibbing, Dominick J. Angiolillo, Heribert Schunkert, Karl Ludwig Laugwitz, Stefanie Schüpke, Adnan Kastrati, Isabell Bernlochner

Research output: Contribution to journal › Letter › peer-review

27 Scopus citations

Original language	English
Pages (from-to)	2569-2571
Number of pages	3
Journal	Journal of the American College of Cardiology
Volume	76
Issue number	21
DOIs	https://doi.org/10.1016/j.jacc.2020.09.586
State	Published - 24 Nov 2020

Access to Document

10.1016/j.jacc.2020.09.586

Cite this

Mayer, K., Bongiovanni, D., Karschin, V., Sibbing, D., Angiolillo, D. J., Schunkert, H., Laugwitz, K. L., Schüpke, S., Kastrati, A., & Bernlochner, I. (2020). Ticagrelor or Prasugrel for Platelet Inhibition in Acute Coronary Syndrome Patients: The ISAR-REACT 5 Trial. Journal of the American College of Cardiology, 76(21), 2569-2571. https://doi.org/10.1016/j.jacc.2020.09.586

@article{a7fad6d5eafb4780a7ab155d28c0da45,

title = "Ticagrelor or Prasugrel for Platelet Inhibition in Acute Coronary Syndrome Patients: The ISAR-REACT 5 Trial",

author = "Katharina Mayer and Dario Bongiovanni and Vincent Karschin and Dirk Sibbing and Angiolillo, {Dominick J.} and Heribert Schunkert and Laugwitz, {Karl Ludwig} and Stefanie Sch{\"u}pke and Adnan Kastrati and Isabell Bernlochner",

note = "Funding Information: This work was funded by the German Center for Cardiovascular Research (DZHK) and Deutsches Herzzentrum M{\"u}nchen. Dr. Sibbing has received lecture fees from Bayer, Sanofi, AstraZeneca, Daiichi-Sankyo, Pfizer, and Roche Diagnostics; has received Advisory Board fees from Bayer, Sanofi, AstraZeneca, Daiichi-Sankyo, and Ferrer; and has received grant support from Roche Diagnostics. Dr. Angiolillo has received consulting fees or honoraria from Abbott, Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The Medicines Company; has received payments for participation in review activities from CeloNova and St. Jude Medical; and has received institutional research grants from Abbott, Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Matsutani Chemical Industry, Merck, Novartis, Osprey Medical, Renal Guard Solutions, and the Scott R. MacKenzie Foundation. Dr. Schunkert has received honoraria from Merck Sharp & Dohme, Amgen, Bayer Vital, Boehringer Ingelheim, Daiichi-Sankyo, Novartis, Servier, Brahms, Bristol Myers Squibb, Medtronic, Sanofi, and Synlab; and has received grant support, paid to his institution, from AstraZeneca. Dr. Sch{\"u}pke has received consulting fees from Bayer Vital; and has received grant support from Else Kr{\"o}ner-Fresenius-Stiftung. Dr. Bernlochner has received lecture fees from Sysmex Europe GmbH. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: This work was funded by the German Center for Cardiovascular Research (DZHK) and Deutsches Herzzentrum M{\"u}nchen. Dr. Sibbing has received lecture fees from Bayer, Sanofi, AstraZeneca, Daiichi-Sankyo, Pfizer, and Roche Diagnostics; has received Advisory Board fees from Bayer, Sanofi, AstraZeneca, Daiichi-Sankyo, and Ferrer; and has received grant support from Roche Diagnostics. Dr. Angiolillo has received consulting fees or honoraria from Abbott, Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The Medicines Company; has received payments for participation in review activities from CeloNova and St. Jude Medical; and has received institutional research grants from Abbott, Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Matsutani Chemical Industry, Merck, Novartis, Osprey Medical, Renal Guard Solutions, and the Scott R. MacKenzie Foundation. Dr. Schunkert has received honoraria from Merck Sharp & Dohme, Amgen, Bayer Vital, Boehringer Ingelheim, Daiichi-Sankyo, Novartis, Servier, Brahms, Bristol Myers Squibb, Medtronic, Sanofi, and Synlab; and has received grant support, paid to his institution, from AstraZeneca. Dr. Sch{\"u}pke has received consulting fees from Bayer Vital; and has received grant support from Else Kr{\"o}ner-Fresenius-Stiftung. Dr. Bernlochner has received lecture fees from Sysmex Europe GmbH. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. ",

year = "2020",

month = nov,

day = "24",

doi = "10.1016/j.jacc.2020.09.586",

language = "English",

volume = "76",

pages = "2569--2571",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier Inc.",

number = "21",

}

Mayer, K, Bongiovanni, D, Karschin, V, Sibbing, D, Angiolillo, DJ, Schunkert, H , Laugwitz, KL , Schüpke, S , Kastrati, A & Bernlochner, I 2020, 'Ticagrelor or Prasugrel for Platelet Inhibition in Acute Coronary Syndrome Patients: The ISAR-REACT 5 Trial', Journal of the American College of Cardiology, vol. 76, no. 21, pp. 2569-2571. https://doi.org/10.1016/j.jacc.2020.09.586

TY - JOUR

T1 - Ticagrelor or Prasugrel for Platelet Inhibition in Acute Coronary Syndrome Patients

T2 - The ISAR-REACT 5 Trial

AU - Mayer, Katharina

AU - Bongiovanni, Dario

AU - Karschin, Vincent

AU - Sibbing, Dirk

AU - Angiolillo, Dominick J.

AU - Schunkert, Heribert

AU - Laugwitz, Karl Ludwig

AU - Schüpke, Stefanie

AU - Kastrati, Adnan

AU - Bernlochner, Isabell

N1 - Funding Information: This work was funded by the German Center for Cardiovascular Research (DZHK) and Deutsches Herzzentrum München. Dr. Sibbing has received lecture fees from Bayer, Sanofi, AstraZeneca, Daiichi-Sankyo, Pfizer, and Roche Diagnostics; has received Advisory Board fees from Bayer, Sanofi, AstraZeneca, Daiichi-Sankyo, and Ferrer; and has received grant support from Roche Diagnostics. Dr. Angiolillo has received consulting fees or honoraria from Abbott, Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The Medicines Company; has received payments for participation in review activities from CeloNova and St. Jude Medical; and has received institutional research grants from Abbott, Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Matsutani Chemical Industry, Merck, Novartis, Osprey Medical, Renal Guard Solutions, and the Scott R. MacKenzie Foundation. Dr. Schunkert has received honoraria from Merck Sharp & Dohme, Amgen, Bayer Vital, Boehringer Ingelheim, Daiichi-Sankyo, Novartis, Servier, Brahms, Bristol Myers Squibb, Medtronic, Sanofi, and Synlab; and has received grant support, paid to his institution, from AstraZeneca. Dr. Schüpke has received consulting fees from Bayer Vital; and has received grant support from Else Kröner-Fresenius-Stiftung. Dr. Bernlochner has received lecture fees from Sysmex Europe GmbH. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: This work was funded by the German Center for Cardiovascular Research (DZHK) and Deutsches Herzzentrum München. Dr. Sibbing has received lecture fees from Bayer, Sanofi, AstraZeneca, Daiichi-Sankyo, Pfizer, and Roche Diagnostics; has received Advisory Board fees from Bayer, Sanofi, AstraZeneca, Daiichi-Sankyo, and Ferrer; and has received grant support from Roche Diagnostics. Dr. Angiolillo has received consulting fees or honoraria from Abbott, Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The Medicines Company; has received payments for participation in review activities from CeloNova and St. Jude Medical; and has received institutional research grants from Abbott, Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Matsutani Chemical Industry, Merck, Novartis, Osprey Medical, Renal Guard Solutions, and the Scott R. MacKenzie Foundation. Dr. Schunkert has received honoraria from Merck Sharp & Dohme, Amgen, Bayer Vital, Boehringer Ingelheim, Daiichi-Sankyo, Novartis, Servier, Brahms, Bristol Myers Squibb, Medtronic, Sanofi, and Synlab; and has received grant support, paid to his institution, from AstraZeneca. Dr. Schüpke has received consulting fees from Bayer Vital; and has received grant support from Else Kröner-Fresenius-Stiftung. Dr. Bernlochner has received lecture fees from Sysmex Europe GmbH. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2020/11/24

Y1 - 2020/11/24

UR - http://www.scopus.com/inward/record.url?scp=85095687671&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2020.09.586

DO - 10.1016/j.jacc.2020.09.586

M3 - Letter

C2 - 33213734

AN - SCOPUS:85095687671

SN - 0735-1097

VL - 76

SP - 2569

EP - 2571

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 21

ER -

Ticagrelor or Prasugrel for Platelet Inhibition in Acute Coronary Syndrome Patients: The ISAR-REACT 5 Trial

Access to Document

Other files and links

Cite this